These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 15797960)
21. Neonatal screening for congenital adrenal hyperplasia. van der Kamp HJ; Wit JM Eur J Endocrinol; 2004 Nov; 151 Suppl 3():U71-5. PubMed ID: 15554889 [TBL] [Abstract][Full Text] [Related]
22. Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance. Votava F; Novotna D; Kracmar P; Vinohradska H; Stahlova-Hrabincova E; Vrzalova Z; Neumann D; Malikova J; Lebl J; Matern D Eur J Pediatr; 2012 Jun; 171(6):935-40. PubMed ID: 22234478 [TBL] [Abstract][Full Text] [Related]
23. Longitudinal measurements of 17alpha-hydroxyprogesterone in premature infants during the first three months of life. Linder N; Davidovitch N; Kogan A; Barzilai A; Kuint J; Mazkeret R; Sack J Arch Dis Child Fetal Neonatal Ed; 1999 Nov; 81(3):F175-8. PubMed ID: 10525018 [TBL] [Abstract][Full Text] [Related]
24. The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis. Ambroziak U; Kępczyńska-Nyk A; Kuryłowicz A; Małunowicz EM; Wójcicka A; Miśkiewicz P; Macech M Clin Endocrinol (Oxf); 2016 Jan; 84(1):23-9. PubMed ID: 26331608 [TBL] [Abstract][Full Text] [Related]
25. Neonatal screening for congenital adrenal hyperplasia: experience and results in Argentina. Gruñieiro-Papendieck L; Chiesa A; Mendez V; Prieto L J Pediatr Endocrinol Metab; 2008 Jan; 21(1):73-8. PubMed ID: 18404975 [TBL] [Abstract][Full Text] [Related]
26. Simultaneous determination of 17alpha-hydroxypregnenolone and 17alpha-hydroxyprogesterone in dried blood spots from low birth weight infants using LC-MS/MS. Higashi T; Nishio T; Uchida S; Shimada K; Fukushi M; Maeda M J Pharm Biomed Anal; 2008 Sep; 48(1):177-82. PubMed ID: 18571354 [TBL] [Abstract][Full Text] [Related]
27. Variable ACTH-stimulated 17-hydroxyprogesterone values in 21-hydroxylase deficiency carriers are not related to the different CYP21 gene mutations. Bachega TA; Brenlha EM; Billerbeck AE; Marcondes JA; Madureira G; Arnhold IJ; Mendonca BB J Clin Endocrinol Metab; 2002 Feb; 87(2):786-90. PubMed ID: 11836321 [TBL] [Abstract][Full Text] [Related]
28. Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol. Miller WL Horm Res Paediatr; 2019; 91(6):416-420. PubMed ID: 31450227 [TBL] [Abstract][Full Text] [Related]
29. Rapid monitoring assay of congenital adrenal hyperplasia with microbore high-performance liquid chromatography/electrospray ionization tandem mass spectrometry from dried blood spots. Lai CC; Tsai CH; Tsai FJ; Lee CC; Lin WD Rapid Commun Mass Spectrom; 2001; 15(22):2145-51. PubMed ID: 11746879 [TBL] [Abstract][Full Text] [Related]
31. Molecular analysis of CYP21A2 can optimize the follow-up of positive results in newborn screening for congenital adrenal hyperplasia. Silveira EL; Elnecave RH; dos Santos EP; Moura V; Pinto EM; van der Linden Nader I; Mendonca BB; Bachega TA Clin Genet; 2009 Dec; 76(6):503-10. PubMed ID: 19930153 [TBL] [Abstract][Full Text] [Related]
32. Neonatal screening for congenital adrenal hyperplasia in North-Eastern Italy: a report three years into the program. Cavarzere P; Camilot M; Teofoli F; Tatò L Horm Res; 2005; 63(4):180-6. PubMed ID: 15818055 [TBL] [Abstract][Full Text] [Related]
33. Influence of spironolactone on neonatal screening for congenital adrenal hyperplasia. Terai I; Yamano K; Ichihara N; Arai J; Kobayashi K Arch Dis Child Fetal Neonatal Ed; 1999 Nov; 81(3):F179-83. PubMed ID: 10525019 [TBL] [Abstract][Full Text] [Related]
34. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. Minutti CZ; Lacey JM; Magera MJ; Hahn SH; McCann M; Schulze A; Cheillan D; Dorche C; Chace DH; Lymp JF; Zimmerman D; Rinaldo P; Matern D J Clin Endocrinol Metab; 2004 Aug; 89(8):3687-93. PubMed ID: 15292289 [TBL] [Abstract][Full Text] [Related]
35. The influence of seasonality and manufacturer kit lot changes on 17α-hydroxyprogesterone measurements and referral rates of congenital adrenal hyperplasia in newborns. Pearce M; Dauerer E; DiRienzo AG; Caggana M; Tavakoli NP Eur J Pediatr; 2017 Jan; 176(1):121-129. PubMed ID: 27900477 [TBL] [Abstract][Full Text] [Related]
36. Analysis of 17 α-hydroxyprogesterone in bloodspots by liquid chromatography tandem mass spectrometry. Salter SJ; Cook P; Davies JH; Armston AE Ann Clin Biochem; 2015 Jan; 52(Pt 1):126-34. PubMed ID: 24842631 [TBL] [Abstract][Full Text] [Related]
37. No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening. Hird BE; Tetlow L; Tobi S; Patel L; Clayton PE Arch Dis Child; 2014 Feb; 99(2):158-64. PubMed ID: 24225272 [TBL] [Abstract][Full Text] [Related]
39. International Newborn Screening Practices for the Early Detection of Congenital Adrenal Hyperplasia. Conlon TA; Hawkes CP; Brady JJ; Loeber JG; Murphy N Horm Res Paediatr; 2024; 97(2):113-125. PubMed ID: 37231960 [TBL] [Abstract][Full Text] [Related]
40. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. Janzen N; Peter M; Sander S; Steuerwald U; Terhardt M; Holtkamp U; Sander J J Clin Endocrinol Metab; 2007 Jul; 92(7):2581-9. PubMed ID: 17456574 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]